Hypertriglyceridemic hyperapoB: The unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus

Annals of Internal Medicine

Volumn 135, Issue 6, 2001, Pages 447-459

  Sniderman, A D ^a   Scantlebury, T ^a   Cianflone, K ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ATHEROGENESIS; ATHEROSCLEROSIS; DYSLIPOPROTEINEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; LIVER METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035909074     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-135-6-200109180-00014     Document Type: Review

References (144)

1. Diabetes and ischemic heart disease
2. What cardiologists need to know about diabetes
3. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
5. International variations in cardiovascular mortality associated with diabetes mellitus: The WHO multinational study of vascular disease in diabetes
6. Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients
7. Increased plasma apolipoprotein B-containing lipoproteins associated with increased urinary albumin within the microalbuminuria range in type 2 diabetes
8. Apolipoprotein, low density lipoprotein subfraction, and insulin associations with familial combined hyperlipidemia. Study of Utah patients with familial dyslipidemic hypertension
9. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles
10. LDL subclass phenotypes and the insulin resistance syndrome in women
11. Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their nonaffected relatives
12. Parental history of diabetes is associated with increased cardiovascular risk factors
13. Cardiovascular risk factors in confirmed prediabetic individuals. Does the dock for coronary heart disease start ticking before the onset of clinical diabetes?
14. Dyslipidemias among normoglycemic members of familial NIDDM pedigrees
15. Lipoprotein composition and serum apolipoproteins in normoglycaemic first-degree relatives of non-insulin dependent diabetic patients
16. Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins]
17. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: Relative contribution of small, dense LDL to coronary heart disease risk
18. Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia, and familial hyper cholesterolemia
19. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B
20. A receptor-mediated pathway for cholesterol homeostasis
21. Triglyceride and Lp(a) concentrations in hyperapobetalipoproteinemia
22. Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels
23. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B
24. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials
25. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material
26. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: Results from the Framingham Offspring Study
27. Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan
28. Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials
29. Lipids and vascular disease: What we do and do not know
30. Identification of multiple subclasses of plasma low density lipoproteins in normal humans
31. Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia
32. Purification and characterization of lipid transfer protein(s) from human lipoprotein-deficient plasma
33. Transfer of cholesterol esters between human high density lipoproteins and triglyceride-rich lipoproteins controlled by a plasma protein factor
34. Low density lipoprotein. A metabolic pathway for return of cholesterol to the splanchnic bed
35. Effects of various non-esterified fatty acids on the transfer of cholestetyl esters from HDL to LDL induced by the cholesteryl ester transfer protein
36. Effect of diabetes on lipoprotein size
37. LDL particle size in relation to insulin, proinsulin, and insulin sensitivity. The insulin resistance atherosclerosis study
38. Inter-relationships between small, dense low-density lipoprotein (LDL), plasma triacylglycerol and LDL apoprotein B in an atherogenic lipoprotein phenotype in free-living subjects
39. Lipoprotein subfraction changes in normal pregnancy: Threshold effect of plasma triglyceride on appearance of small, dense low density lipoprotein
40. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease
41. Distribution of lipids in 8,500 men with coronary artery disease
42. Triglyceride: The forgotten risk factor
43. Epidemiology of hypertriglyceridemia and cardiovascular disease
44. High-density lipoproteins in human health and disease
45. High density lipoprotein and coronary heart disease: Insights from mutations leading to low high density lipoprotein
46. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis
47. Paraoxonase and coronary heart disease
48. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis
49. Serum and lipoprotein apolipoprotein B levels in normal subjects and patients with hyperlipoproteinaemia
50. Myocardial infarction in the familial forms of hypertriglyceridemia
51. Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction
52. High prevalence of hypertriglyceridaemia and apolipoprotein abnormalities in coronary artery disease
53. Clinical significance of measurements of serum apolipoprotein A-I, A-II and B in hypertriglyceridemic male patients with and without coronary artery disease
54. Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged < or = 50 years) and women (< or = 60 years) with coronary artery disease
55. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study)
56. Comparison of arterial intimal clearances of LDL from diabetic and nondiabetic cholesterol-fed rabbits. Differences in intimal clearance explained by size differences
57. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system
58. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction
59. Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study
60. Small, dense LDL particle concentration correlates with plasminogen activator inhibitor type-1 (PAI-1) activity
61. Low density lipoprotein subfractions increase thromboxane formation in endothelial cells
62. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects
63. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia
64. Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages
65. Influence of plasma lipid LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans
66. Low density lipoprotein subfractions and [Ca2+]i in vascular smooth muscle cells
67. Modulation of apolipoprotein B antigenic determinants in human low density lipoprotein subclasses
68. Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size
69. Studies of low density lipoprotein molecular weight in human beings with coronary artery disease
70. Low-density lipoprotein subclass patterns and risk of myocardial infarction
71. Low density lipoprotein particle size and coronary artery disease
72. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women
73. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women
74. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
75. LDL size and risk of coronary heart disease in elderly men and women
76. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study
77. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men
78. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS)
79. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk intervention Project
80. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression
81. Evidence for a new pathophysiological mechanism for coronary artery disease regression: Hepatic lipase-mediated changes in LDL density
82. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study
83. Lipoprotein metabolism in diabetes mellitus
84. Abnormal lipoprotein metabolism in non-insulin-dependent diabetes mellitus. Pathogenesis and treatment
85. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus
86. Serum lipids and lipoproteins in insulin-dependent diabetic subjects during high-carbohydrate, high-fiber diet
87. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes
88. The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients
89. Carbohydrate-induced hypertriacylglycerolemia: Historical perspective and review of biological mechanisms
90. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases
91. Molecular pathobiology of the human lipoprotein lipase gene
92. Low-density lipoprotein size, high-density lipoprotein concentration, and endothelial dysfunction in non-insulin-dependent diabetes
93. Glycosylated low density lipoprotein is more sensitive to oxidation: Implications for the diabetic patient?
94. Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity
95. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein
96. Substrate delivery as a determinant of hepatic apoB secretion
97. Role of cholesterol ester mass in regulation of secretion of ApoB100 lipoprotein particles by hamster hepatocytes and effects of statins on that relationship
98. Stimulation of fatty acid biosynthesis by dietary cholesterol and of cholesterol synthesis by dietary fatty acid
99. Governance of the concentration of plasma LDL: A reevaluation of the LDL receptor paradigm
100. Apolipoprotein B in the rough endoplasmic reticulum: Translation, translocation and the initiation of lipoprotein assembly
101. Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normolipidemic subjects
102. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects
103. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in obesity: A stable isotope study
104. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM
105. Effects of insulin on cholesterol synthesis in type II diabetes patients
106. Acute hyperinsulinaemia decreases cholesterol synthesis less in subjects with non-insulin-dependent diabetes mellitus than in non-diabetic subjects
107. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM
108. Relation of plasma triglyceride and apoB levels to insulin-mediated suppression of nonesterified fatty acids. Possible explanation for sex differences in lipoprotein pattern
109. Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Relation to plasma triglyceride and apolipoprotein B concentrations
110. The adipocyte, fatty acid trapping, and atherogenesis
111. Regulation of lipid and lipoprotein metabolism by PPAR activators
112. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus
113. Fatty acids in the portal vein of the rat regulate hepatic insulin clearance
114. Effect of fatty acids on glucose production and utilization in man
115. The antilipolytic action of insulin in obese subjects with resistance to its glucoregulatory action
116. Plasma and lipoprotein cholesterol and triglyceride concentrations in the Pima Indians: Distributions differing from those of Caucasians
117. Studies of very low density lipoprotein triglyceride metabolism in an obese population with low plasma lipids: Lack of influence of body weight or plasma insulin
118. Integrated study of low density lipoprotein metabolism and very low density lipoprotein metabolism in non-insulin-dependent diabetes
119. Low incidence of fatal coronary heart disease in Pima Indians despite high prevalence of non-insulin-dependent diabetes
120. Coronary heart disease prevalence and its relation to risk factors in American Indians. The Strong Heart Study
121. Fasting and postprandial plasma concentrations of acylation-stimulation protein (ASP) in lean and obese Pima Indians compared to Caucasians
122. Skeletal muscle triglyceride levels are inversely related to insulin action
123. Tissue triglycerides, insulin resistance, and insulin production: Implications for hyperinsulinemia of obesity
124. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
125. Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy
126. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia
127. Effect of gemfibrozil on the concentration and composition of very iow density and low density lipoprotein subfractions in hypertriglyceridemic patients
128. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus
129. Atherogenic lipoprotein phenotype in type 2 diabetes: Reversal with micronised fenofibrate
130. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study
131. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study
132. Metabolic modes of action of the statins in the hyperlipoproteinemias
133. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
134. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
135. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
136. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study
137. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial
138. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
139. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol
140. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial
141. Thrombogenic factors and recurrent coronary events
142. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events
143. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
144. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)